Cargando…

Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors

BACKGROUND: Vitamin K antagonists are widely used in the treatment and prevention of thromboembolic disease. However, these drugs can cause serious side effects, especially bleeding. This study aims to evaluate frequency and risk factors of both bleeding and asymptomatic overdose in North African pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben Mbarka, F., Ben Jeddou, K., Allouche, E., Boukhris, I., Khalfallah, N., Baccar, H., Ouahchi, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Egyptian Society of Cardiology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883498/
https://www.ncbi.nlm.nih.gov/pubmed/29622997
http://dx.doi.org/10.1016/j.ehj.2018.01.001
_version_ 1783311666281185280
author Ben Mbarka, F.
Ben Jeddou, K.
Allouche, E.
Boukhris, I.
Khalfallah, N.
Baccar, H.
Ouahchi, Z.
author_facet Ben Mbarka, F.
Ben Jeddou, K.
Allouche, E.
Boukhris, I.
Khalfallah, N.
Baccar, H.
Ouahchi, Z.
author_sort Ben Mbarka, F.
collection PubMed
description BACKGROUND: Vitamin K antagonists are widely used in the treatment and prevention of thromboembolic disease. However, these drugs can cause serious side effects, especially bleeding. This study aims to evaluate frequency and risk factors of both bleeding and asymptomatic overdose in North African patients undergoing Vitamin K antagonist therapy. METHODS: We performed a cross-sectional study in patients undergoing Vitamin K antagonist therapy. A statistical analysis has been conducted to identify overdose and bleeding risk factors by using chi-square test (p < .05). RESULTS: One hundred and eleven patients were included. We recorded 14 cases of bleeding and 26 cases of asymptomatic overdose. Advanced age, poor adherence, concomitant use of paracetamol and history of previous bleeding are significant risk factors of over-anticoagulation. An INR value over 6 at admission, a high therapeutic target range for INR, concomitant use of acetylsalicylic acid, lack of information on overdose signs and measures to be taken in case of bleeding were identified as risk factors for bleeding. CONCLUSION: Most of the risk factors identified in our study seem to be related to patients lack of information and education. These results highlight the importance of creating a therapeutic patient education program.
format Online
Article
Text
id pubmed-5883498
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Egyptian Society of Cardiology
record_format MEDLINE/PubMed
spelling pubmed-58834982018-04-05 Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors Ben Mbarka, F. Ben Jeddou, K. Allouche, E. Boukhris, I. Khalfallah, N. Baccar, H. Ouahchi, Z. Egypt Heart J Miscellaneous BACKGROUND: Vitamin K antagonists are widely used in the treatment and prevention of thromboembolic disease. However, these drugs can cause serious side effects, especially bleeding. This study aims to evaluate frequency and risk factors of both bleeding and asymptomatic overdose in North African patients undergoing Vitamin K antagonist therapy. METHODS: We performed a cross-sectional study in patients undergoing Vitamin K antagonist therapy. A statistical analysis has been conducted to identify overdose and bleeding risk factors by using chi-square test (p < .05). RESULTS: One hundred and eleven patients were included. We recorded 14 cases of bleeding and 26 cases of asymptomatic overdose. Advanced age, poor adherence, concomitant use of paracetamol and history of previous bleeding are significant risk factors of over-anticoagulation. An INR value over 6 at admission, a high therapeutic target range for INR, concomitant use of acetylsalicylic acid, lack of information on overdose signs and measures to be taken in case of bleeding were identified as risk factors for bleeding. CONCLUSION: Most of the risk factors identified in our study seem to be related to patients lack of information and education. These results highlight the importance of creating a therapeutic patient education program. Egyptian Society of Cardiology 2018-03 2018-02-01 /pmc/articles/PMC5883498/ /pubmed/29622997 http://dx.doi.org/10.1016/j.ehj.2018.01.001 Text en © 2018 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Miscellaneous
Ben Mbarka, F.
Ben Jeddou, K.
Allouche, E.
Boukhris, I.
Khalfallah, N.
Baccar, H.
Ouahchi, Z.
Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors
title Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors
title_full Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors
title_fullStr Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors
title_full_unstemmed Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors
title_short Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors
title_sort bleeding and asymptomatic overdose in patients under vitamin k antagonist therapy: frequency and risk factors
topic Miscellaneous
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883498/
https://www.ncbi.nlm.nih.gov/pubmed/29622997
http://dx.doi.org/10.1016/j.ehj.2018.01.001
work_keys_str_mv AT benmbarkaf bleedingandasymptomaticoverdoseinpatientsundervitaminkantagonisttherapyfrequencyandriskfactors
AT benjeddouk bleedingandasymptomaticoverdoseinpatientsundervitaminkantagonisttherapyfrequencyandriskfactors
AT allouchee bleedingandasymptomaticoverdoseinpatientsundervitaminkantagonisttherapyfrequencyandriskfactors
AT boukhrisi bleedingandasymptomaticoverdoseinpatientsundervitaminkantagonisttherapyfrequencyandriskfactors
AT khalfallahn bleedingandasymptomaticoverdoseinpatientsundervitaminkantagonisttherapyfrequencyandriskfactors
AT baccarh bleedingandasymptomaticoverdoseinpatientsundervitaminkantagonisttherapyfrequencyandriskfactors
AT ouahchiz bleedingandasymptomaticoverdoseinpatientsundervitaminkantagonisttherapyfrequencyandriskfactors